We present a nationwide prospective Swedish registry-based study of Waldenstr€ om macroglobulinaemia (WM), that focuses on incidence and survival in relation to clinical prognostic factors and primary systemic therapies. A total of 1511 patients with WM and lymphoplasmocytic lymphoma (LPL) were registered in the Swedish Lymphoma Registry (SLR) between 1 January 2000 and 31 December 2014. The age-adjusted incidence of WM/LPL was 11Á5 per million persons per year, three times higher than the reported incidence worldwide. Medical records were retrieved for 1135 patients (75%). A retrospective review showed that 981 (86Á1%) of these patients fulfilled the World Health Organization diagnostic criteria for WM and these patients were analysed further. The overall survival (OS) improved between two periods -2000-2006 and 2007-2014 -with a fiveyear OS of 61% and 70%, respectively. Significant prognostic factors for OS, evaluated at the time of diagnosis, were age, elevated lactate dehydrogenase level and haemoglobin ≤115 g/l for patients receiving therapy 0-3 months after diagnosis, and age, poor performance status, haemoglobin ≤115 g/l, and female sex in "watch and wait" patients (multivariable analysis). The level of the IgM monoclonal immunoglobulin had no significant prognostic value. Rituximab included in first-line therapy was associated with improved survival.
Waldenstr€ om macroglobulinaemia (WM)/lymphoplasmacytic lymphoma (LPL) is a rare disease, with a worldwide incidence of 3-4 per million persons per year (Wang et al, 2012; Brandefors et al, 2016) . The diagnosis of WM requires infiltration of LPL cells in the bone marrow and any concentration of IgM monoclonal immunoglobulin (MI) (Owen et al, 2003; Swerdlow et al, 2008) . Common clinical manifestations of WM include anaemia and thrombocytopenia due to tumour infiltration in bone marrow, enlarged lymph nodes and spleen, recurrent fever, night sweats, fatigue and weight loss. High concentrations of IgM MI can cause hyperviscosity and an increase in plasma volume with resulting anaemia due to dilution of red cells (Vitolo et al, 2008; Ghobrial, 2012) .
Several prognostic factors have been identified, mostly in small patient cohorts and in non-population retrospective analyses (Facon et al, 1993; Morel et al, 2000; Owen et al, 2001; Dimopoulos et al, 2003; Merlini et al, 2003; Ghobrial et al, 2006; Dhodapkar et al, 2009; Kastritis et al, 2009) . The most widely accepted prognostic index, the International Prognostic Scoring System for WM (IPSSWM; Morel et al, 2009) , is based on disease parameters evaluated at the time of first-line treatment. The indications for therapy applied in the original IPSSWM cohort were defined by the 2nd International Workshop recommendations (Kyle et al, 2003) and a bone marrow lymphoplasmacytic infiltration of more than 20% was required. Many WM patients do not exhibit symptoms at diagnosis (i.e., smouldering or asymptomatic WM) and do not require any therapy, so why there is a need to explore prognostic factors at the time for diagnosis? In this article we explore the prognostic factors for patients treated 0-3 months after diagnosis, and also for asymptomatic patients managed with a "watch and wait" strategy.
Waldenstr€ om macroglobulinaemia is a rare disease and only a few randomized studies on treatment have been published (Buske et al, 2009; Leblond et al, 2013; Rummel et al, 2013) . Therefore, treatment guidelines are mostly based on results from phase II trials and retrospective data. Mostly the choice of first-line therapy is based on the individual patient's characteristic and disease symptoms and immunochemotherapy is currently the standard treatment for most WM patients (Buske et al, 2013; Treon, 2015; Leblond et al, 2016; Gertz, 2017) .
Although WM remains an incurable disease, the median overall survival (OS) has improved, ranging from 6 years in the 1990s to 8 years in the first decade of the 2000s (Kristinsson et al, 2013; Castillo et al, 2015) .
We present data from an analysis based on a nationwide prospective high-quality registry of the lymphoma population in Sweden with 15 years follow-up. Our study focuses on the incidence and outcome of WM in relation to clinical prognostic factors and primary systemic therapies.
The results from this unselected cohort of patients provide novel knowledge of this rare disease that can be applied to patients treated during routine clinical care.
Patients and methods

Swedish lymphoma registry
The Swedish Cancer Registry (SCR), established in 1958, is a compulsory registry for all newly diagnosed cancers in Sweden. All cancer subtypes are reported to the SCR both by the responsible pathologist and the treating physician. To obtain specific complementary information for lymphoma, such as clinical stage, prognostic factors and treatment, the Swedish Lymphoma Group (SLG) initiated a specific Swedish Lymphoma Registry (SLR) in 2000.
The coverage of SLR is high; >95% of the adult patients (>18 years of age) with a lymphoma diagnosis in the SCR are included also in the SLR (Swedish lymphoma register 2014; http://www.swedishlymphoma.se/rapporter). Between 2000 and 2006, data are incomplete regarding type of first-line treatment, but after 1 January 2007, when a more detailed web-based registry was introduced, most first-line therapies have been recorded in the registry.
Study population
From the SLR, we collected 1511 patients living in Sweden, a country with approximately 10 million inhabitants, who were diagnosed with WM/LPL between 1 January 2000 and 31 December 2014. A large proportion of the patients were reported to the registry as the broader diagnosis WM/LPL. To confirm WM diagnosis, data were extracted from the medical records of the 1511 patients registered in SLR. In total, 1139 of these (75%) had available serum protein electrophoresis, including immunofixation, and the pathology report of the bone marrow biopsy/aspiration and/or lymph node biopsy at the time of diagnosis and 981 (86Á1%) fulfilled the criteria for WM (Fig 1) . In Sweden, the World Health Organization (WHO) diagnostic criteria for WM are used, including morphological infiltration of LPL in the bone marrow (without a defined percentage of tumour cells) and an IgM MI of any concentration in serum (https://www.ca ncercentrum.se/samverkan/cancerdiagnoser/blod-lymfom-mye lom/lymfom-lymfkortelcancer/vardprogram/gallande-vardpro gram-waldenstroms-makroglobulinemi/). The definition of non-WM LPL included disease without a serum IgM MI. Also, patients with a lymph node infiltration with LPL cells but without a bone marrow infiltration and/or without IgM MI were defined as non-WM LPL.
In total, 124 patients (10Á9%) fulfilled these LPL criteria (29 with IgG MI and 7 with IgA MI) and were analysed only for the total incidence of WM/LPL but excluded from other analyses. The non-WM LPL patients will be described elsewhere.
In addition, 16 (1Á4%) patients were excluded because they were incorrectly registered as WM (Fig 1; Table SI ) and 18 (1Á6%) patients were excluded due to incomplete data on IgM MI in serum and/or bone marrow infiltration.
For the analysis of prognostic factors, we used the following data from the time point of diagnosis, collected from the SLR: age, lactate dehydrogenase (LDH) level, B-symptoms, WHO performance status (WHO PS; Oken et al, 1982) , gender, haemoglobin, albumin, lymphocyte counts, time point for start of first-line treatment and time point for death. If these data were missing in the SLR, supplementary data were extracted from the medical records regarding haemoglobin, albumin, LDH, platelet count, beta-2 microglobulin (b2M), IgM MI level and immunoglobulin levels.
The analysis included the prognostic factors used in IPSSWM (Morel et al, 2009); age, haemoglobin (≤115 g/l) , platelet count (≤100 9 10 9 /l), b2M (>3 mg/l) and IgM MI (>70 g/l). In addition, we used the median value of albumin for the cohort (≤35 g/l) and divided WHO PS into two groups; WHO PS 0 and WHO PS 1-4. (Oken et al, 1982) . IgM MI was analysed both with continuous and dichotomous scales with three different cut-offs (30, 50 and 70 g/l). Hypogammaglobinaemia was defined as an immunoglobulin value below the lower level of the reference interval used by the individual laboratory. The recommended workup in the Swedish national guidelines for patients with lymphoma include biopsy from bone marrow (and lymph node or other lymphoma involved site when applicable) as well as computed tomography (CT) scan of thorax, abdomen and pelvis and laboratory tests. In the registry, only 55% of the patients with WM/LPL had a complete recommended workup, and in most cases CT scan data and data on lymph node involvement were missing.
Date of start of first-line treatment and type of initial therapy were collected from the SLR. Because data on treatment outcome, relapses, and secondline treatment were missing for many patients, these data were excluded from further analysis.
In summary, of the 1511 patients registered in the SLR, 981 were confirmed as WM patients and were analysed in more detail (Fig 1) . Therapy was initiated within 0-3 months after diagnosis in 297 patients, and the type of systemic therapy was reported in 203 of these patients. This study was approved by the regional ethics committee of Ume a (2011-44-31M) . A specific informed consent from the patients was not required as the study was mainly based on registry data. The study was conducted in accordance with the Declaration of Helsinki.
Statistical analysis
All statistical analyses were performed in the free software environment R version 3.0.2 (some analyses were performed in version 3.3.2) and the packages "survival" (Pohar Perme, 2013; Gerds, 2014; Therneau, 2015) . Incidence calculation was done by age-adjusting (i.e., a weighted average of all the age-specific incidences), using the "European Standard Survival analysis was performed by both ordinary overall survival (OS) and relative survival (RS) methods. The Kaplan-Meier method was used to estimate OS and the subsequent curves were compared using log-rank test (Harrington & Fleming, 1982) . RS was estimated by the Pohar-Perme estimator (Pohar Perme, 2013 ) and the subsequent survival curves were compared using a log-rank type test (Graffeo et al, 2016) . Life tables (of the population of Sweden) required for RS analysis were downloaded from the Human Mortality Database (https://www.mortality.org/). The median follow-up time was estimated using reverse Kaplan-Meier (Schemper & Smith, 1996) .
Results
Incidence for WM/LPL
Using data collected from the SLR (1511 patients) between 1 January and 31 December 2014 the age-adjusted incidence for WM/LPL was 11Á5 per million persons per year. The ageadjusted incidence for males during the same period was 15Á5 per million males per year and the corresponding figure for females was 8Á5. There were no significant changes in incidence rates over time for the two different genders. Incidence increased with age: <65 years, 3Á4; 65-75 years, 32Á7; >75 years, 45Á5 per million persons per year, respectively. For the patients receiving therapy 0-3 months after diagnosis the age-adjusted incidence was 2Á3 per million persons per year.
The age-adjusted incidence for WM/LPL varies between the different counties in Sweden (Fig 2) .
Incidence for WM
The overall age-adjusted incidence for WM in Sweden could not be calculated because of incomplete data of the specific diagnosis in 372 patients. However, in the cohort of 1139 patients with a confirmed diagnosis, 981 (86Á1%) were classified as WM. If the proportion of WM patients and the age distribution of WM patients is the same in the WM/LPL population as in the smaller cohort with confirmed WM diagnosis, the overall age-adjusted incidence for WM can be estimated. Per the assumptions outlined above, the estimated incidence for WM would be 86Á1% of the calculated incidence for the whole WM/LPL cohort, i.e., 9Á9 per million persons per year. In Norrbotten and V€ asterbotten, the two counties with complete diagnostic data, the true age-adjusted incidences for WM were 17Á6 and 14Á3 per million persons per year, respectively.
WM patient clinical characteristics
The diagnosis of WM was confirmed in 981 patients (86Á1%) based on LPL infiltration in bone marrow and serum IgM MI. Patient characteristics regarding age, gender and prognostic factors are described in Table I . Only 26 patients (2Á7%) were diagnosed before 50 years of age and 721 (73Á5%) patients were older than 65 years. The median follow-up time from diagnosis for survival for all patients was 79Á9 months. By the end of the observation period (7 October 2015), 449 (45Á8%) patients had died. B-symptoms were present at diagnosis in 143 (14Á6%) of the patients; the most frequent B-symptom was weight loss (89 patients, 9Á1%), followed by night sweats (73 patients, 7Á4%) and fever (24 patients, 2Á4%) (Table II) . This table also presents data on patients receiving therapy 0-3 months after diagnosis (n = 297) and on "watch and wait" patients (n = 684).
WM survival
The median OS of all WM patients (2000-2014) was 96 months and the three-year and five-year survival was 78% and 66%, respectively. The OS was worse for WM patients receiving therapy 0-3 months after diagnosis compared with "watch and wait" patients, with a five-year survival of 61% and 68%, respectively (see Figure S1 ). Kaplan-Meier and RS curves for the two periods (2000-2006 and 2007-2014, respectively) The OS increased in the three cohorts between the time periods 2000-2006 and 2007-2014 (Fig 3) .
Age was a strong prognostic factor (Fig 4) . Compared to the younger patients, the elderly had worse OS (P < 0Á001) and RS, although the OS was improved in all age groups between 2000-2006 and 2007-2014 (data not shown) .
Kaplan-Meier curves showed no difference in survival between male and females (P = 0Á18 and P = 0Á46, respectively).
WM prognostic factors
Univariate and multivariable analysis in all WM patients. In univariate analysis, significant prognostic factors evaluated at the time of diagnosis in all WM patients (n = 981) were: age, WHO PS, elevated LDH, B-symptoms, time of diagnosis (2000-2006 or 2007-2014) , albumin ≤35 g/l, haemoglobin ≤115 g/l, platelet count ≤100 9 10 9 /l, lymphocytosis ≥5 9 10 9 /l and b2M >3 mg/l (Table II) . b2M data was not required in the SLR and b2M data could be extracted for only 200 (20Á4%) patients from the medical records. Lymphocyte and platelet counts were not registered in SLG until 2007, and we could extract data for 614 (62Á6%) and 643 (65Á5%) patients respectively.
b2M level, platelet count and lymphocyte count were significant prognostic factors according to univariate analysis; however, these variables were not included in the multivariable analysis due to the many missing values.
The serum level of the IgM MI at diagnosis was not a significant prognostic factor in univariate analysis, calculated with both continuous and dichotomous scales with different cut-off values, 30 and 50 g/l, respectively. In addition, the cut-off used in the IPSSWM (70 g/l) showed no prognostic value in univariate analysis. However, in total only 33 (3Á5%) of the WM patients had an IgM MI >70 g/l at diagnosis. Hypogammaglobinaemia and type of light chain (kappa or lambda) were of no prognostic value.
The multivariable analysis revealed that age, WHO PS, LDH level and haemoglobin ≤115 g/l were still significant prognostic factors. Female sex was not a significant prognostic factor in the univariate analysis but emerged as a positive prognostic factor in the multivariable analysis (Table II) .
Univariate and multivariable analysis of prognostic factors in WM patients receiving therapy 0-3 months after diagnosis and "watch and wait" WM patients. Univariate and multivariable analyses of prognostic factors for OS were performed separately for the patients whose therapy was initiated 0-3 months after diagnosis (n = 297) and for "watch and wait "patients (n = 684) ( Table II) . The univariate analysis showed the same prognostic factors as for all WM patients, except that albumin ≤35 g/l, for the cohort that received early therapy, and gender and B-symptoms, for the "watch and wait" cohort, were not significant prognostic factors. In the multivariable analysis, age, haemoglobin ≤115 g/l and elevated LDH remained significant prognostic factors in the cohort that received therapy at diagnosis, and age, female sex, WHO PS and haemoglobin ≤115 g/l remained significant prognostic factors for the "watch and wait" cohort. Neither the level of the IgM MI calculated with continuous scale nor IgM MI >70 g/l was a significant prognostic factor in any of the patient groups (Table II) . However, only 13/ 684 (1Á9%) of the "watch and wait" patients and 20/297 (6Á7%) of the patients receiving early therapy (0-3 months after diagnosis) had an IgM MI >70 g/l.
Systemic therapies (n = 203). In Sweden, rituximab was introduced as a routine treatment for WM patients in a population-based setting as late as 2008. Data on 111 patients treated with rituximab 0-3 months after diagnosis are available; 32 of these patients received rituximab monotherapy. Table III lists the distribution of the most commonly used chemotherapies. When comparing OS and RS in patients treated with single rituximab, rituximab-containing chemotherapies and chemotherapies alone, patients treated with rituximab-containing therapies had the longest survival (P < 0Á001) (Fig 5) .
Both the univariate (HR 4Á268, 95% CI 2Á521-7Á667, P < 0Á001) and multivariable analysis showed that patients treated with rituximab-containing therapies had significant improved OS compared to patients treated with chemotherapy alone. When adjusting for age, WHO PS, sex, haemoglobin ≤115 g/l and LDH, the HR was 0Á405 (95% CI 0Á223-0Á738, P = 0Á003) for rituximab-containing therapies compared with chemotherapies alone.
Gender and choice of systemic therapies. The choice of treatment with different chemotherapies tended to differ between males and females, but the treatment groups were generally too small for significance testing. However, females were more often treated with chlorambucil than males (60% vs. 30%, P < 0Á001). In general, patients treated with chlorambucil were older and had more adverse prognostic factors, but there was no age difference between males and females (Table III) . The overall use of rituximab (P = 0Á259) did not differ between the genders, nor did the prognostic factors, such as age, LDH and haemoglobin ≤115 g/l, except that females had WHO PS 1-4 more often than males (62% vs. 41%).
Discussion
Waldenstr€ om macroglobulinaemia is a rare disease with a worldwide incidence of 3-4 million persons per year and this rate varies between geographical areas: US = 3Á8 Table I . Patient characteristics in all WM patients (n = 981), WM patients with first line treatment 0-3 months after diagnosis (n = 297) and "watch and wait" WM patients (n = 684), diagnosed in Sweden 2000-2014.
All patients with diagnosis of WM (n = 981) WM patients with first line treatment 0-3 months after diagnosis (n = 297) WM patients with no treatment within 3 months of diagnosis, "watch and wait" (n = 684) 
b2M, b2-microglobulin; CI, confidence interval; HR, hazard ratio; LDH, lactate dehydrogenase; MI, monoclonal immunoglobulin; WHO PS, Word Health Organization performance status; WM, Waldenstr€ om macroglobulinaemia. (Wang et al, 2012) , South East England = 5Á5 (Phekoo et al, 2008) and Japan = 0Á43 (Iwanaga et al, 2014) . We observed a three times higher incidence of WM in Sweden (11Á5 per million persons per year) and an even higher incidence in northern Sweden (Brandefors et al, 2016) . Contributing factors to this could be that Sweden has a mandatory cancer registry and a high proportion of WM patients with asymptomatic disease at diagnosis are followed with a "watch and wait" policy (73Á4%), while the corresponding figure in the literature is approximately onequarter of the patients (Pophali et al, 2018) . Counties with a low incidence (≤0Á7) had more symptomatic patients requiring therapy at diagnosis than counties with a high incidence (≥1Á2), 31% and 15%, respectively, and inferior survival (P < 0Á001). On the other hand, Norrbotten, the county with the highest incidence, had the same frequency of patients requiring therapy as counties with low incidence. Generally, Sweden follows the 2nd International Workshop recommendations for initiating therapy (Kyle et al, 2003) . The differences in incidences between the counties in Sweden may partly reflect different organization of healthcare, availability to haematologists and haematopathologists, and local practices regarding the time at which to bone marrow biopsies are performed. Another factor is different diagnostic criteria: one example is the Mayo Clinic criteria, which require an infiltration of >10% LPL cells in the bone marrow (Kapoor et al, 2017) . Moreover, all of the above-mentioned incidence studies used different standard populations (2000 US standard population, European standard population and WHO standard population) when calculating the age-adjusted incidence. It is known that the WHO standard population has a comparable young population structure and thus will, in the case of a disease of elderly, yield lower incidence rates. In this article we therefore chose to use European 2013 standard population.
The incidence of WM has geographical, ethnic and gender differences and there are associations with immune conditions and family history of haematological malignancy for the development of WM (Ekstr€ om Kristinsson et al, 2008 Kristinsson et al, , 2010 . We have observed aggregations of families with WM and a co-occurrence with autoimmune diseases in the northern Sweden (Brandefors et al, 2016) , a region with a small but stable and, in some areas, isolated population. This suggests that both genetic and environmental factors can influence the incidence of disease. This part of Sweden also has low sun exposure, especially in the winter, and several studies indicate an increased risk of lymphoma with decreased sun exposure (Kricker et al, 2008) . In addition, WM incidence is higher in males. Being male is a wellknown risk factor for many subtypes of lymphomas and haematological malignancies, but the underlying causes of these associations remain unknown (Abrahamsson et al, 2014; Ellin et al, 2014) . Occupational and environmental exposure are potential risk factors, but there are no convincing data to confirm that relationship; only a few studies have been conducted, and these studies report mixed results (Linet et al, 1993; Royer et al, 2010; Vajdic et al, 2014) . The literature indicates that about 5% of the WM/LPL patients fulfil the diagnostic criteria for non-WM LPL (Swerdlow et al, 2008) . In our study the proportion is higher. One explanation is that we have included patients with an IgM MI but without bone marrow involvement in the non-WM LPL group. Further, there are known diagnostic difficulties in the diagnosis of WM/LPL and a review of the diagnosis in patients not fulfilling the WM criteria (non-WM LPL) by a haematopathologist is ongoing.
We confirmed that most of the established prognostic factors used at time of first therapy were also relevant at diagnosis in univariate and multivariable analysis. However, the level of the IgM MI was of no prognostic value neither in the whole cohort nor in the patients receiving first-line therapies at diagnosis. The IgM MI level as a prognostic factor is controversial as some studies indicate a correlation between the level of the IgM and survival (Morel et al, 2000; GarciaSanz et al, 2001; Dhodapkar et al, 2009 ) One explanation could be that IgM levels correlate more to the differentiation of plasma cells than to the overall tumour burden in the bone marrow (Treon, 2015) .
We included all patients (patients with treatment at diagnosis and "watch and wait" patients) in the analysis because the need for a prognostic index for all patients at the time of diagnosis is important. Other prognostic indexes for indolent lymphomas (such as the Follicular Lymphoma International Prognostic Index for follicular lymphomas and Rai-Binet for chronic lymphocytic leukaemia) are used for all patients at diagnosis. The most established prognostic index for WM (i.e., the IPSSWM) is only validated at the time for the first line treatment, while a large proportion of WM patients are asymptomatic ("wait and watch" patients) at diagnosis. In addition, we also analysed prognostic factors for patients receiving first line therapy at diagnosis and "watch and wait" patients, separately. As in the data from the Greek Myeloma Study Group (Kastritis et al, 2010) , elevated LDH emerged as a significant prognostic factor in the cohort receiving therapy 0-3 months after diagnosis, this was not seen in the "watch and wait" cohort. LDH is a prognostic factor in many other subtypes of lymphomas, but it is not included in the IPSSWM.
Waldenstr€ om macroglobulinaemia is a disease of the elderly with a median age of 73 years at diagnosis and age was one of the strongest prognostic factors in the present study. Unrelated WM mortality is significant in this mostly elderly cohort and should be considered when choosing treatment and estimating survival (Castillo et al, 2015; Kastritis et al, 2015) . RS better reflects the disease-specific mortality and the differences between the older and younger cohorts have decreased during the last several years. Competing risk survival analysis is another useful tool for evaluating long-term outcome of WM; however, this approach was unavailable to us because we did not have access to data on competing causes of death. Both the OS and the RS improved between the two periods (2000-2006 and 2007-2014) , a finding that agrees with other recent studies. Most of the earlier registry studies included LPL/WM; however, our study included only WM (Kristinsson et al, 2013; Castillo et al, 2014) . Data from previous studies (Kristinsson et al, 2013) as well as preliminary data from the SLR (unpublished observations) suggest that WM has better survival than LPL.
One possible reason for the improved survival is the introduction of better chemo-and immunotherapies, such as rituximab-containing therapies. In Sweden, different chemotherapy regimens have been used at different time periods. For example, fludarabine was used in younger patients until 2010, when fludarabine was mostly replaced by bendamustine. Recently, the use of dexamethasone, rituximab and cyclophosphamide (DRC) has increased as first-line therapy, especially after 2013 when the national guidelines recommended this combination. Chlorambucil was used during the entire study period, often as treatment in older patients with comorbidity.
Rituximab has improved the survival for WM patients (Fig 5; Table II ). When rituximab is used in combination with chemotherapy, the overall response rate (ORR) is between 80% and 95% (Buske et al, 2009; Leblond et al, 2016) . Rituximab used without chemotherapy has a lower ORR, between 30% and 50% (Dimopoulos et al, 2002; Gertz et al, 2004; Treon et al, 2005) , and is mostly used in patients with low tumour burden and in some fragile patients. Improvements in supportive care, for example, prophylactic treatment of infections, may also partly explain the improved OS in recent years.
Treatment choice for males and females tended to differ. Females more often received chlorambucil, which is an older and relatively inexpensive therapy, and single rituximab, which is considered a milder treatment. Males, on the other hand, received more intensive therapies, such as fludarabine and bendamustine, which are considered more modern therapies but with more side-effects. That is, males more often than females received more intensive treatments (fludarabine, bendamustine and CHOP [cyclophosphamide, doxorubicin, vincristine, prednisone] ) (P = 0Á014). These results must be interpreted with caution as the sample size is small. Little is known about gender difference in the treatment of haematological malignancies, especially lymphomas; as a result, more research is needed to investigate how gender influences choice of therapy. Gender imbalances with respect to medical treatment in general is well known and have been discussed, as equal care is a goal in health care (Hamberg et al, 2002; Borkhoff et al, 2009; Sharma et al, 2015) . Gender and socioeconomic imbalances could be improved by developing and implementing national guidelines for both diagnostic criteria and treatment. Our study has several strengths. Sweden has a long tradition of high quality population-based registries. The SLR covers approximately 95% of the population, which is high compared to other studies without the possibility to linkage through registries.
This study is a large population-based study of a rare disease, based on the entire Swedish population diagnosed over 15 years, with access to clinical data, such as exact lymphoma subtype, prognostic factors and detailed treatment, so selection bias is minimized. These data provide important information about outcome, prognostic factors and treatments in this unselected cohort. Prognostic factors were only available at diagnoses and calculations on prognostic factors in relation to OS were made for all patients and for the cohort that needed treatment 0-3 month after diagnosis, thus lead-time bias was avoided.
The study also has some limitations. The following data were not available or were incomplete: type of treatment before 2007 and important prognostic factors for calculating the IPSSWM, such as platelet count and b2M, treatment outcome, number of relapses, second-line treatments, comorbidity and cause of death. The diagnosis of WM according to the 2008 WHO classification includes infiltration of LPL in the bone marrow and a MI of IgM type of any size (Swerdlow et al, 2008) . In the 2016 revision of the WHO classifications, the disease-defining mutation MYD88 L265P was added as this mutation is found in about 90% of WM and in a significant proportion of IgM MGUS patients (Swerdlow et al, 2016) . A limitation in our study is the lack of pathology review and lack of data regarding the MYD88 L265P mutation, which had not been performed in most cases.
In summary, our population-based study compared survival in a large unselected cohort of patients with WM in relation to clinical prognostic factors and therapies. Survival increased over time and established prognostic factors available at the time of diagnosis significantly influenced survival, except the IgM MI level. In addition, we provide support that rituximab is essential in the treatment of WM and is associated with improved survival.
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